Published in

BMJ Publishing Group, Thorax, 2(78), p. 207-210, 2022

DOI: 10.1136/thorax-2022-219192

Links

Tools

Export citation

Search in Google Scholar

Plasma thymic stromal lymphopoietin (TSLP) in adults with non-severe asthma: the EGEA study

Journal article published in 2022 by Bakari Ibrahim ORCID, Djamal Achour, Farid Zerimech, Patricia de Nadai, Valerie Siroux ORCID, Anne Tsicopoulos, Régis Matran, Vanessa Granger, Rachel Nadif ORCID
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Thymic stromal lymphopoietin (TSLP), a cytokine involved in severe asthma treatment, was never studied in non-severe asthma.Among 969 adults from a large epidemiological study, cross-sectional analyses showed that plasma TSLP levels were associated with increased age and BMI, male sex, smoking and high TSLP levels (one IQR increase) with current asthma and poor lung function. High TSLP levels were also associated with persistence of asthma attacks (aOR=2.14 (95% CI 1.23 to 3.72)) and dyspnoea (aOR=2.71 (95% CI 1.39 to 5.28)) 10 years later.Our results suggest that TSLP could be a cytokine of interest in non-severe asthma, and its determinants of circulating levels could be considered in asthma management.